Denmark · Delayed Price · Currency is DKK CTI BioPharma Statistics
Total Valuation
Embla Medical has a market cap or net worth of DKK 12.90 billion. The enterprise value is 15.92 billion.
| Market Cap | 12.90B |
| Enterprise Value | 15.92B |
Important Dates
The last earnings date was Tuesday, July 22, 2025.
| Earnings Date | Jul 22, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Embla Medical has 425.84 million shares outstanding. The number of shares has decreased by -0.80% in one year.
| Current Share Class | 425.84M |
| Shares Outstanding | 425.84M |
| Shares Change (YoY) | -0.80% |
| Shares Change (QoQ) | -3.69% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 73.52% |
| Float | 160.26M |
Valuation Ratios
The trailing PE ratio is 27.72 and the forward PE ratio is 22.37. Embla Medical's PEG ratio is 1.25.
| PE Ratio | 27.72 |
| Forward PE | 22.37 |
| PS Ratio | 2.33 |
| PB Ratio | 2.43 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 20.62 |
| P/OCF Ratio | 16.99 |
| PEG Ratio | 1.25 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.34, with an EV/FCF ratio of 25.45.
| EV / Earnings | 34.27 |
| EV / Sales | 2.87 |
| EV / EBITDA | 14.34 |
| EV / EBIT | 19.79 |
| EV / FCF | 25.45 |
Financial Position
The company has a current ratio of 1.79, with a Debt / Equity ratio of 0.68.
| Current Ratio | 1.79 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.68 |
| Debt / EBITDA | 3.35 |
| Debt / FCF | 5.74 |
| Interest Coverage | 5.72 |
Financial Efficiency
Return on equity (ROE) is 9.27% and return on invested capital (ROIC) is 5.58%.
| Return on Equity (ROE) | 9.27% |
| Return on Assets (ROA) | 4.66% |
| Return on Invested Capital (ROIC) | 5.58% |
| Return on Capital Employed (ROCE) | 8.47% |
| Revenue Per Employee | 1.39M |
| Profits Per Employee | 116,142 |
| Employee Count | 4,061 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 2.15 |
Taxes
In the past 12 months, Embla Medical has paid 143.68 million in taxes.
| Income Tax | 143.68M |
| Effective Tax Rate | 23.48% |
Stock Price Statistics
The stock price has decreased by -1.94% in the last 52 weeks. The beta is 0.59, so Embla Medical's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -1.94% |
| 50-Day Moving Average | 33.00 |
| 200-Day Moving Average | 32.72 |
| Relative Strength Index (RSI) | 36.70 |
| Average Volume (20 Days) | 31,101 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Embla Medical had revenue of DKK 5.55 billion and earned 464.57 million in profits. Earnings per share was 1.09.
| Revenue | 5.55B |
| Gross Profit | 3.48B |
| Operating Income | 766.18M |
| Pretax Income | 612.03M |
| Net Income | 464.57M |
| EBITDA | 900.36M |
| EBIT | 766.18M |
| Earnings Per Share (EPS) | 1.09 |
Balance Sheet
The company has 597.82 million in cash and 3.59 billion in debt, giving a net cash position of -3.00 billion or -7.03 per share.
| Cash & Cash Equivalents | 597.82M |
| Total Debt | 3.59B |
| Net Cash | -3.00B |
| Net Cash Per Share | -7.03 |
| Equity (Book Value) | 5.31B |
| Book Value Per Share | 12.40 |
| Working Capital | 1.26B |
Cash Flow
In the last 12 months, operating cash flow was 759.38 million and capital expenditures -133.76 million, giving a free cash flow of 625.62 million.
| Operating Cash Flow | 759.38M |
| Capital Expenditures | -133.76M |
| Free Cash Flow | 625.62M |
| FCF Per Share | 1.47 |
Margins
Gross margin is 62.73%, with operating and profit margins of 13.81% and 8.37%.
| Gross Margin | 62.73% |
| Operating Margin | 13.81% |
| Pretax Margin | 11.03% |
| Profit Margin | 8.37% |
| EBITDA Margin | 16.23% |
| EBIT Margin | 13.81% |
| FCF Margin | 11.28% |
Dividends & Yields
Embla Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.80% |
| Shareholder Yield | n/a |
| Earnings Yield | 3.60% |
| FCF Yield | 4.85% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Embla Medical has an Altman Z-Score of 2.99 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.99 |
| Piotroski F-Score | 6 |